FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
← catalyst calendarSponsored by Fate Therapeutics (industry) · FATE — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
This study was withdrawn (Sponsor decision).
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Dec 2022 | estimated | When the study began enrolling |
| Primary completion | May 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2039 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diffuse Large B Cell Lymphoma
- Transformed Indolent Non-Hodgkin's Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
Interventions
- Drug: FT596
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Vincristine
- Drug: Prednisone
- Drug: Rituximab — also filed as Rituxan, Truxima, Ruxience
- Drug: Bendamustine — also filed as Bendeka, Treanda
Primary outcomes
what the primary-completion date above is the date OFIncidence of dose-limiting toxicities within each dose escalation cohort
measured Day 21
Nature of dose-limiting toxicities within each dose escalation cohort
measured Day 21
Incidence, nature, and severity of adverse events (AEs) of FT596 in combination with R-CHOP in B-cell lymphoma previously untreated or no more than one previous line of therapy with severity determined according to NCI CTCAE, v5.0
measured Up to 5 years
Permalink · FATE's whole pipeline · Catalyst calendar · Every registered study · What changed